iSpecimen Inc. (NASDAQ:ISPC) Sees Large Decline in Short Interest

iSpecimen Inc. (NASDAQ:ISPC) was the target of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 79,700 shares, a decline of 33.1% from the February 28th total of 119,100 shares. Currently, 9.7% of the company’s shares are short sold. Based on an average trading volume of 841,800 shares, the short-interest ratio is currently 0.1 days.

iSpecimen Price Performance

Shares of ISPC stock traded down $0.03 during trading hours on Friday, hitting $1.15. The company had a trading volume of 28,437 shares, compared to its average volume of 411,960. iSpecimen has a fifty-two week low of $1.09 and a fifty-two week high of $11.80. The company’s fifty day moving average is $1.74 and its 200 day moving average is $3.14. The stock has a market capitalization of $1.11 million, a PE ratio of -0.06 and a beta of 1.65.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iSpecimen stock. Bridgeway Capital Management LLC bought a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 21,800 shares of the company’s stock, valued at approximately $58,000. Bridgeway Capital Management LLC owned approximately 2.27% of iSpecimen at the end of the most recent quarter. 13.62% of the stock is owned by institutional investors.

iSpecimen Company Profile

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.